Literature DB >> 23909936

Psoriasis and dyslipidemia: a population-based study analyzing the National Health and Nutrition Examination Survey (NHANES).

C Ma1, C W Schupp, E J Armstrong, A W Armstrong.   

Abstract

BACKGROUND: Psoriasis has been linked to an increased incidence of coronary artery disease, stroke, myocardial infarctions and cardiovascular deaths. Dyslipidemia, a well-established risk factor for cardiovascular disease, involves inflammatory pathways that are also implicated in psoriasis. An understanding of the relationship between psoriasis and dyslipidemia may have a substantial clinical impact.
OBJECTIVE: This study aimed to examine the association between psoriasis and multiple measurements of dyslipidemia, which include levels of triglycerides, apolipoprotein B, LDL-cholesterol, HDL-cholesterol, HDL/LDL ratio and total cholesterol.
METHODS: We conducted a population-based, cross-sectional study using the National Health and Nutrition Examination Survey (NHANES) 2003-2006 and 2009-2010. NHANES is a national research survey programme conducted biennially to evaluate the health and nutritional status of the U.S. population. The survey uses a multistage, stratified design. NHANES data were collected from questionnaires, physical examination and laboratory values.
RESULTS: The sample population consisted of 13 418 adults who provided responses to their psoriasis status. A total of 353 (2.63%) participants reported a health care provider-given diagnosis of psoriasis. The multivariate analysis showed that psoriasis was not significantly associated with certain measures of dyslipidemia from this population. Specifically, in psoriasis patients, the weighted odds ratio (OR) of total cholesterol >200 mg/dL was 0.96 (95% CI 0.74-1.24); weighted OR of HDL-cholesterol <40 mg/dL was 0.92 (95% CI 0.65-1.30); weighted OR of LDL-cholesterol >130 mg/dL was 0.67 (95% CI 0.43-1.03); weighted OR of triglycerides >150 mg/dL was 1.20 (95% CI 0.89-1.63); weighted OR of apolipoprotein B >130 mg/dL was 1.29 (95% CI 0.69-2.41); weighted OR of HDL/LDL <0.4 was 1.20 (95% CI 0.8-1.79).
CONCLUSION: Based on the NHANES data 2003-2006 and 2009-2010, psoriasis is not significantly associated with alterations in certain lipid levels. Larger sample sizes may be necessary to detect appreciable differences in the lipid levels between patients with and without psoriasis.
© 2013 European Academy of Dermatology and Venereology.

Entities:  

Mesh:

Year:  2013        PMID: 23909936     DOI: 10.1111/jdv.12232

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  14 in total

1.  Association Between Oxidation-Modified Lipoproteins and Coronary Plaque in Psoriasis.

Authors:  Alexander V Sorokin; Kazuhiko Kotani; Youssef A Elnabawi; Amit K Dey; Aparna P Sajja; Shingo Yamada; Masashi Ueda; Charlotte L Harrington; Yvonne Baumer; Justin A Rodante; Joel M Gelfand; Marcus Y Chen; Aditya A Joshi; Martin P Playford; Alan T Remaley; Nehal N Mehta
Journal:  Circ Res       Date:  2018-11-09       Impact factor: 17.367

Review 2.  Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background.

Authors:  Giulia Ganzetti; Anna Campanati; Elisa Molinelli; Annamaria Offidani
Journal:  World J Cardiol       Date:  2016-02-26

3.  Prevalence of chronic axial pain, inflammatory back pain, and spondyloarthritis in diagnosed psoriasis.

Authors:  Nicole Thom; Christopher T Ritchlin; Xiao Zhang; John Reveille; Michael H Weisman
Journal:  Arthritis Care Res (Hoboken)       Date:  2015-05       Impact factor: 4.794

4.  Effectiveness of Lipid-Lowering Statin Therapy in Patients With and Without Psoriasis.

Authors:  William C Ports; Rana Fayyad; David A DeMicco; Rachel Laskey; Robert Wolk
Journal:  Clin Drug Investig       Date:  2017-08       Impact factor: 2.859

Review 5.  Updates on cardiovascular comorbidities associated with psoriatic diseases: epidemiology and mechanisms.

Authors:  Kaitlyn M Yim; April W Armstrong
Journal:  Rheumatol Int       Date:  2016-05-24       Impact factor: 2.631

Review 6.  New Frontiers in Psoriatic Disease Research, Part II: Comorbidities and Targeted Therapies.

Authors:  Di Yan; Andrew Blauvelt; Amit K Dey; Rachel S Golpanian; Samuel T Hwang; Nehal N Mehta; Bridget Myers; Zhen-Rui Shi; Gil Yosipovitch; Stacie Bell; Wilson Liao
Journal:  J Invest Dermatol       Date:  2021-04-19       Impact factor: 7.590

Review 7.  Psoriasis-associated vascular disease: the role of HDL.

Authors:  Maria Joao Paiva-Lopes; José Delgado Alves
Journal:  J Biomed Sci       Date:  2017-09-14       Impact factor: 8.410

Review 8.  Biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis.

Authors:  Rosario Peluso; Francesco Caso; Marco Tasso; Vincenzo Sabbatino; Roberta Lupoli; Matteo Nicola Dario Di Minno; Francesco Ursini; Luisa Costa; Raffaele Scarpa
Journal:  Open Access Rheumatol       Date:  2019-06-28

9.  High-density lipoprotein cholesterol function improves after successful treatment of psoriasis: a step forward in the right direction.

Authors:  Nehal N Mehta; Joel M Gelfand
Journal:  J Invest Dermatol       Date:  2014-03       Impact factor: 8.551

10.  Primary care-based screening for cardiovascular risk factors in patients with psoriasis.

Authors:  M K Rutter; K Kane; M Lunt; L Cordingley; A Littlewood; H S Young; C A Chew-Graham; R Hilton; D P M Symmons; C E M Griffiths
Journal:  Br J Dermatol       Date:  2016-07-12       Impact factor: 9.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.